Katren Holding Publishes Marketing Annual Report for 2019
Katren JSC has published its annual marketing report on the results of the holding’s activities in 2019 on its site, www.katrengroup.ru
The document presents the key business directions and the main results for each company in Katren JSC.
As Vladimir Spiridonov, General Director of Katren JSC, pointed out in his address, one of the key tendencies in the pharmaceutical market in 2019 was the redistribution of market shares between distributors: wholesalers minimize risks by refusing to work with unreliable clients. In 2020 Katren JSC plans, in all the markets in which it operates - Russia,Kazakhstan, Belorussia and Ukraine - to develop in accordance with established strategy, and will continue to focus on reducing risks, maintaining profit levels, and optimizing logistics processes. Moreover Katren JSC will uphold the high standards of work which it has developed over the years.
In March 2020, the World Health Organization declared the beginning of a global pandemic, caused by a new form of coronavirus (COVID-19). Governments were forced to adopt a range of measures limiting the spread of the virus. These measures have had a significant impact on global financial markets and posed operational challenges to companies in different sectors of economy. The Group’s management is continuing to assess the possible effect that these circumstances may have on the Company’s activities.
As a participant in a socially significant industry, in the context of the restrictions caused by the pandemic, the Group helps to provide the population with necessary medicines, including through the services apteka.ru / apteka.com, whose popularity has especially increased in conditions of social distance and self-isolation. In the current situation, the Company’s main priorities remain the health and safety of people, including the staff of Group entities, and also the maintenance of high quality standards.
In 2019, the Group’s turnover was 234 billion roubles, and the net profit for the company’s shareholders was 1.8 billion roubles.
The Group’s 2019 reports were audited by the independent auditing company Deloitte and Touche CIS.
Katren JSC annual marketing report for 2019 can be found in the “About the Group/ Annual Marketing Report” section on the Holding’s site.
The main Holding’s company - JSC NPC Katren - operates as a distributor of medicines in all federal districts and constituent entities of the Russian Federation. In 2019, the Company reported gross revenue of 183.6 billion roubles, and a net profit of 2.1 billion roubles.
In 2019 Melodiya Zdorovya pharmacy network as a retail segment took the first place among federal pharmacy networks in the category of networks with a medium turnover of up to 2 million roubles a month per pharmacy (RNC Pharma). In 2019 the Company reported a 52% growth in sales turnover in its own network of pharmacies. As at the end of 2019, the pharmacy network had 808 pharmacies in 52 constituent entities of the Russian Federation.
The Annual Marketing Report does not constitute an annual report for the purposes of Chapter 70 of Provisions of the Russian Central Bank No. 454-P On the Disclosure of Information by Issuers of Securities, dated December 30, 2014. The text of the annual report prepared in accordance with these requirements will be published on this page as a result of its approval by the General Meeting of Shareholders.
Information about the Company
Katren JSC is the holding company of the Group, operating in pharmaceutical markets, in the distribution and retail sectors. Katren JSC main business is concentrated in the Russian Federation, and it also operates as a pharmaceutical distributor in Ukraine, Kazakhstan and Belarus.